Skip to content

Use of the SWAMECO Questionnaire Basel

Use of the SWAMECO Questionnaire in the General Population to Detect Swallowing Difficulties

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04238559
Acronym
SWAMECO
Enrollment
115
Registered
2020-01-23
Start date
2019-02-11
Completion date
2019-04-09
Last updated
2020-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Swallowing Difficulties

Brief summary

A patient self-report questionnaire was developed that assesses subjective swallowing difficulties with medication intake, the SWAMECO questionnaire. It was validated in a highly specific population and will now be tested in the general population.

Detailed description

Based on a systematic literature review, a novel self-report questionnaire was developed in 2016 to assess subjective swallowing difficulties with medication intake and their practical consequences in ambulatory patients, the SWAMECO questionnaire. It consists of 30 items divided into 5 sections Complaints, Intensity, Localization, Coping strategies, and Adherence to medication. It was validated in people suffering from systemic sclerosis (SSc), a rare multisystem autoimmune disease that often leads to swallowing problems with food and liquids with progression. The aim of this study is now to validate the questionnaire in the general population. Patients presenting in the community pharmacy with a prescription of at least 3 different medications for a minimum of 3 months will fill in the questionnaire on site.

Interventions

Fill in the SWAMECO questionnaire

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 years or more * is living in the community setting * is receiving three or more medications for a period not less than three months, independently of the frequency of the intake

Exclusion criteria

* patients who are not able to provide written conformed consent will be excluded

Design outcomes

Primary

MeasureTime frameDescription
swallowing difficulties assessed by Questionnaire5 minutesThe variable of primary interest is the answer to the question number 4: Do you experience swallowing difficulties when you take your medicines?

Secondary

MeasureTime frameDescription
medication adherence assessed by Questionnaire5 minutesAnswers to q 26-28: how many days did you miss at least one dose of any of your medicines?, how good a job did you do at taking your medicines in the way you were supposed to?, how often did you take your medicines in the way you were supposed to?

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026